Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad vs Benzbromarone in Hyperuricemia with or without Gout
NCT03100318Phase 3Completed
- Sponsor
- Fuji Yakuhin
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dotinurad in hyperuricemia and gout (2 arms), sponsored by Fuji Yakuhin. Primary endpoint: Percent reduction from baseline in serum urate level at 14 weeks. Started Apr 2017; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT03100318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100318.